PE20020272A1 - N-oxidos de derivados de 4-fenil-piridina como prodrogas de los antagonistas del receptor de neuroquinina 1 (nk-1) - Google Patents
N-oxidos de derivados de 4-fenil-piridina como prodrogas de los antagonistas del receptor de neuroquinina 1 (nk-1)Info
- Publication number
- PE20020272A1 PE20020272A1 PE2001000704A PE2001000704A PE20020272A1 PE 20020272 A1 PE20020272 A1 PE 20020272A1 PE 2001000704 A PE2001000704 A PE 2001000704A PE 2001000704 A PE2001000704 A PE 2001000704A PE 20020272 A1 PE20020272 A1 PE 20020272A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- phenyl
- trifluoromethyl
- oxides
- pyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
SE REFIERE A N-OXIDOS DE DERIVADOS DE 4-FENIL-PIRIDINA DE FORMULA I DONDE R ES H, ALQUILO, ALCOXILO, HALOGENO, TRIFLUOROMETILO; R1 ES H, HALO; R Y R1 PUEDEN ESTAR JUNTOS CON LOS ATOMOS DE CARBONO DEL ANILLO A LOS QUE ESTAN UNIDOS -CH=CH-CH=CH-; R2 Y R2' SON H, HALOGENO, TRIFLUOROMETILO, ALCOXILO, CIANO; R3 Y R3' SON H, ALQUILO, CICLOALQUILO; R4 Y R4' SON -(CH2)mOR6, ALQUILO; R4 Y R4' FORMAN JUNTO CON EL ATOMO DE N AL QUE ESTAN UNIDOS UNA AMINA TERCIARIA CICLICA DEL GRUPO a ; R5 ES H, OH, ALQUILO, ENTRE OTROS; R6 ES H, ALQUILO, FENILO; X ES -C(O)N(R6)-, ENTRE OTROS; n ES 0-4; m ES 1-3. SON COMPUESTOS PREFERIDOS ESTER TERC-BUTILICO DEL ACIDO 4-{5-[(3,5-BIS-TRIFLUOROMETIL-BENCIL)-METIL-CARBAMOIL-4-o-TOLIL-PIRIDIN-2-IL}-4-OXI-PIPERAZIN-1-CARBOXILICO, ESTER ETILICO DEL ACIDO 5'-[(3,5-BIS-TRIFLUOROMETIL-BENCIL)-METIL-CARBAMOIL-4-o-TOLIL-1-OXI-3,4,5,6-TETRAHIDRO-2H-[1,2']PIRIDINIL-4-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCESO PARA LA PREPARACION. LOS N-OXIDOS DE DERIVADOS DE 4-FENIL-PIRIDINA COMO PRODROGAS DE LOS ANTAGONISTAS DEL RECEPTOR DE NEUROQUININA 1 (NK-1) SON UTILES PARA EL TRATAMIENTO DE CONDICIONES INFLAMATORIAS, MIGRANA, ARTRITIS REUMATOIDEA, ASMA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00115287 | 2000-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20020272A1 true PE20020272A1 (es) | 2002-04-16 |
Family
ID=8169262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2001000704A PE20020272A1 (es) | 2000-07-14 | 2001-07-13 | N-oxidos de derivados de 4-fenil-piridina como prodrogas de los antagonistas del receptor de neuroquinina 1 (nk-1) |
Country Status (39)
Country | Link |
---|---|
US (4) | US6593472B2 (es) |
EP (1) | EP1303490B1 (es) |
JP (1) | JP3950044B2 (es) |
KR (1) | KR100501608B1 (es) |
CN (1) | CN1178917C (es) |
AR (1) | AR029717A1 (es) |
AT (1) | ATE400556T1 (es) |
AU (1) | AU7061901A (es) |
BR (1) | BRPI0112475B8 (es) |
CA (1) | CA2415890C (es) |
CY (1) | CY1108557T1 (es) |
CZ (1) | CZ303639B6 (es) |
DE (1) | DE60134749D1 (es) |
DK (1) | DK1303490T3 (es) |
EC (1) | ECSP034431A (es) |
EG (1) | EG24968A (es) |
ES (1) | ES2309075T3 (es) |
GT (1) | GT200100137A (es) |
HK (1) | HK1058198A1 (es) |
HR (1) | HRP20030003B1 (es) |
HU (1) | HU230316B1 (es) |
IL (2) | IL153834A0 (es) |
JO (1) | JO2372B1 (es) |
MA (1) | MA26929A1 (es) |
ME (1) | ME01311B (es) |
MX (1) | MXPA03000366A (es) |
MY (1) | MY154976A (es) |
NO (1) | NO324700B1 (es) |
NZ (1) | NZ523273A (es) |
PA (1) | PA8522001A1 (es) |
PE (1) | PE20020272A1 (es) |
PL (1) | PL205207B1 (es) |
PT (1) | PT1303490E (es) |
RS (1) | RS50932B (es) |
RU (1) | RU2266284C2 (es) |
SI (1) | SI1303490T1 (es) |
UY (1) | UY26839A1 (es) |
WO (1) | WO2002006236A1 (es) |
ZA (1) | ZA200210207B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2208205T3 (es) * | 1999-11-29 | 2004-06-16 | F. Hoffmann-La Roche Ag | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida. |
CZ303639B6 (cs) * | 2000-07-14 | 2013-01-23 | F. Hoffmann-La Roche Ag | N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem |
TWI287003B (en) * | 2000-07-24 | 2007-09-21 | Hoffmann La Roche | 4-phenyl-pyridine derivatives |
CA2444395C (en) * | 2001-04-23 | 2010-12-21 | F. Hoffmann-La Roche Ag | Use of nk-1 receptor antagonists against benign prostatic hyperplasia |
CA2530886C (en) * | 2003-07-03 | 2013-05-28 | F. Hoffmann-La Roche Ag | Dual nk1/nk3 antagonists for treating schizophrenia |
CA2572645C (en) | 2004-07-06 | 2011-01-18 | F. Hoffmann-La Roche Ag | Process for preparing carboxamide derivatives used as intermediates in the synthesis of nk-1 receptor antagonists |
US20060030600A1 (en) * | 2004-08-06 | 2006-02-09 | Patrick Schnider | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia |
CA2598762A1 (en) | 2005-02-25 | 2006-08-31 | F. Hoffmann-La Roche Ag | Tablets with improved drug substance dispersibility |
ES2320590T3 (es) * | 2005-03-23 | 2009-05-25 | F. Hoffmann-La Roche Ag | Metabolitos para antagonistas nk-1 para emesis. |
JP2008280248A (ja) * | 2005-11-02 | 2008-11-20 | Eisai R & D Management Co Ltd | アルツハイマー型痴呆症治療薬塩酸ドネペジルのプロドラッグ |
CN101641099A (zh) | 2007-01-24 | 2010-02-03 | 葛兰素集团有限公司 | 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物 |
GB0808747D0 (en) | 2008-05-14 | 2008-06-18 | Glaxo Wellcome Mfg Pte Ltd | Novel compounds |
US8966414B2 (en) | 2009-05-29 | 2015-02-24 | Cypress Semiconductor Corporation | Implementing a circuit using an integrated circuit including parametric analog elements |
US9858367B1 (en) | 2009-08-31 | 2018-01-02 | Cypress Semiconductor Corporation | Integrated circuit including parametric analog elements |
EP2361090B1 (en) | 2009-11-18 | 2014-05-21 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
CN106974912A (zh) | 2011-10-18 | 2017-07-25 | 赫尔辛医疗股份公司 | 奈妥匹坦和帕洛诺司琼的治疗性组合 |
US8426450B1 (en) | 2011-11-29 | 2013-04-23 | Helsinn Healthcare Sa | Substituted 4-phenyl pyridines having anti-emetic effect |
ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
PT3738434T (pt) | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
CN111454200A (zh) * | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
EP3067349B1 (en) | 2013-11-08 | 2018-02-28 | Kissei Pharmaceutical Co., Ltd. | Carboxymethyl piperidine derivative |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
US10350098B2 (en) * | 2013-12-20 | 2019-07-16 | Volcano Corporation | Devices and methods for controlled endoluminal filter deployment |
SI3102208T1 (sl) | 2014-02-07 | 2021-07-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
TWI649307B (zh) | 2014-05-07 | 2019-02-01 | 日商橘生藥品工業股份有限公司 | Cyclohexylpyridine derivative |
CN106588899B (zh) * | 2015-10-15 | 2019-11-15 | 江苏恒瑞医药股份有限公司 | 吡啶基取代的6-氧杂螺[4.5]癸烷类衍生物、其制备方法及其在医药上的应用 |
MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
US11160809B2 (en) | 2017-04-10 | 2021-11-02 | Chase Therapeutics Corporation | NK1-antagonist combination and method for treating synucleinopathies |
BR112019028034A2 (pt) | 2017-06-30 | 2020-07-07 | Chase Therapeutics Corporation | composições de antagonista de nk-1 e métodos para uso no tratamento da depressão |
US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56106286A (en) | 1980-01-28 | 1981-08-24 | Nippon Musical Instruments Mfg | Electronic musical instrument |
EP0103545A3 (en) | 1982-09-13 | 1984-10-03 | Arc Technologies Systems, Ltd. | Electrode for arc furnaces |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
PL181214B1 (pl) | 1993-12-29 | 2001-06-29 | Merck Sharp & Dohme | Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
DE19627431A1 (de) * | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
AR008789A1 (es) * | 1996-07-31 | 2000-02-23 | Bayer Corp | Piridinas y bifenilos substituidos |
US5972938A (en) | 1997-12-01 | 1999-10-26 | Merck & Co., Inc. | Method for treating or preventing psychoimmunological disorders |
CZ20013046A3 (cs) * | 1999-02-24 | 2002-02-13 | F. Hoffmann-La Roche Ag | Fenylové a pyridinylové deriváty |
ATE277905T1 (de) * | 1999-02-24 | 2004-10-15 | Hoffmann La Roche | 4-phenylpyridinderivate und deren verwendung als nk-1 rezeptorantagonisten |
ES2208205T3 (es) * | 1999-11-29 | 2004-06-16 | F. Hoffmann-La Roche Ag | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-otolil-piridin-3-il)-isobutiramida. |
CZ303639B6 (cs) * | 2000-07-14 | 2013-01-23 | F. Hoffmann-La Roche Ag | N-Oxid derivátu 4-fenylpyridinu, zpusob jeho prípravy a lécivo s jeho obsahem |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
-
2001
- 2001-07-09 CZ CZ20030428A patent/CZ303639B6/cs not_active IP Right Cessation
- 2001-07-09 KR KR10-2003-7000476A patent/KR100501608B1/ko active IP Right Grant
- 2001-07-09 MX MXPA03000366A patent/MXPA03000366A/es active IP Right Grant
- 2001-07-09 WO PCT/EP2001/007850 patent/WO2002006236A1/en active IP Right Grant
- 2001-07-09 ES ES01949475T patent/ES2309075T3/es not_active Expired - Lifetime
- 2001-07-09 ME MEP-2008-770A patent/ME01311B/me unknown
- 2001-07-09 AU AU7061901A patent/AU7061901A/xx active Pending
- 2001-07-09 DE DE60134749T patent/DE60134749D1/de not_active Expired - Lifetime
- 2001-07-09 RU RU2003102612/04A patent/RU2266284C2/ru active
- 2001-07-09 DK DK01949475T patent/DK1303490T3/da active
- 2001-07-09 RS YUP-6/03A patent/RS50932B/sr unknown
- 2001-07-09 AT AT01949475T patent/ATE400556T1/de active
- 2001-07-09 PL PL365684A patent/PL205207B1/pl unknown
- 2001-07-09 BR BRPI0112475A patent/BRPI0112475B8/pt not_active IP Right Cessation
- 2001-07-09 CA CA002415890A patent/CA2415890C/en not_active Expired - Lifetime
- 2001-07-09 JP JP2002512140A patent/JP3950044B2/ja not_active Expired - Lifetime
- 2001-07-09 IL IL15383401A patent/IL153834A0/xx unknown
- 2001-07-09 SI SI200130848T patent/SI1303490T1/sl unknown
- 2001-07-09 HU HU0301311A patent/HU230316B1/hu unknown
- 2001-07-09 NZ NZ523273A patent/NZ523273A/en not_active IP Right Cessation
- 2001-07-09 EP EP01949475A patent/EP1303490B1/en not_active Expired - Lifetime
- 2001-07-09 PT PT01949475T patent/PT1303490E/pt unknown
- 2001-07-09 CN CNB018128246A patent/CN1178917C/zh not_active Expired - Lifetime
- 2001-07-10 JO JO2001106A patent/JO2372B1/en active
- 2001-07-11 EG EG2001070771A patent/EG24968A/xx active
- 2001-07-11 PA PA20018522001A patent/PA8522001A1/es unknown
- 2001-07-12 US US09/904,059 patent/US6593472B2/en not_active Expired - Lifetime
- 2001-07-12 GT GT200100137A patent/GT200100137A/es unknown
- 2001-07-12 MY MYPI20013310A patent/MY154976A/en unknown
- 2001-07-13 AR ARP010103335A patent/AR029717A1/es active IP Right Grant
- 2001-07-13 UY UY26839A patent/UY26839A1/es not_active IP Right Cessation
- 2001-07-13 PE PE2001000704A patent/PE20020272A1/es active IP Right Grant
-
2002
- 2002-12-17 ZA ZA200210207A patent/ZA200210207B/en unknown
-
2003
- 2003-01-02 HR HR20030003A patent/HRP20030003B1/xx not_active IP Right Cessation
- 2003-01-07 IL IL153834A patent/IL153834A/en active IP Right Grant
- 2003-01-07 US US10/337,543 patent/US6747026B2/en not_active Expired - Lifetime
- 2003-01-13 MA MA26997A patent/MA26929A1/fr unknown
- 2003-01-13 NO NO20030154A patent/NO324700B1/no not_active IP Right Cessation
- 2003-01-14 EC EC2003004431A patent/ECSP034431A/es unknown
- 2003-07-09 US US10/616,276 patent/US6897226B2/en not_active Expired - Lifetime
- 2003-08-21 US US10/645,895 patent/US6806370B2/en not_active Expired - Lifetime
-
2004
- 2004-02-12 HK HK04100947A patent/HK1058198A1/xx not_active IP Right Cessation
-
2008
- 2008-10-07 CY CY20081101108T patent/CY1108557T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20020272A1 (es) | N-oxidos de derivados de 4-fenil-piridina como prodrogas de los antagonistas del receptor de neuroquinina 1 (nk-1) | |
ES2171109A1 (es) | Derivados de 4-fenil-piridina. | |
AU2001272476A1 (en) | Piperidines for use as orexin receptor antagonists | |
YU8703A (sh) | Derivati 4-fenil-piridina kao antagonisti receptora neurokinina-1 | |
FI956270A0 (fi) | Piperdiinijohdannaisia ja menetelmä niiden valmistamiseksi | |
DE69405864T2 (de) | Verfahren zur Herstellung von quaternären Diestern | |
PE20030761A1 (es) | Derivados del 7-amino-benzotiazol | |
BG104287A (en) | Halogensubstituted tetracyclic derivatives of tetrahydrofuran | |
MY123467A (en) | Preparation of sterically hindered amine ethers | |
HU900636D0 (en) | Process for preparation of new tetrahydro-benzimidazole derivatives and pharmaceutical compositions containing the above compounds | |
NO932998L (no) | Nye 4,5-dihydro-4-okso-pyrrolo(1,2-a) kinoksaliner og tilsvarende aza-analoger of fremgangsmaate for fremstilling av dem | |
SE7501365L (es) | ||
PE20030719A1 (es) | Derivados de 8-[bis(2-halofenil)metil]-3-heteroaril-8-azabiciclo[3.2.1] octan-3-ol como agonistas del receptor de nociceptina orl-1 | |
PE20010649A1 (es) | Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos | |
EA199900043A1 (ru) | ПРОИЗВОДНЫЕ ПИРИДИЛКАРБАМОИЛИНДОЛИНОВ В КАЧЕСТВЕ АНТАГОНИСТОВ 5-НТ2с-РЕЦЕПТОРОВ | |
IT1303123B1 (it) | Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed | |
AR009666A1 (es) | Compuestos derivados de carboxamida ciclicos sustituidos con carboxi, composicion farmaceutica, usos en la fabricacion de composiciones farmaceuticas para el asma, la tos y la bronquitis y procedimiento de preparacion | |
PL240855A1 (en) | Process for preparing novel,base-substituted 4-phenyl-4,5,6,7-tetrahydrothieno/2,3-c/pyridines | |
EA200400469A1 (ru) | Замещенные производные алкиламинопиридазинона, способ их получения и содержащие их фармацевтические композиции | |
DK0452000T3 (da) | Fremgangsmåde til fremstilling af optisk aktive norbornylaminderivater | |
GB2004885A (en) | Indolopyrones | |
JPS5524127A (en) | 3,6-endomethylene-delta4-1,2,3,6-tetrahydrophtalimide derivative | |
TH62385A (th) | อนุพันธ์ของเฮเทอโรแอริล ที่เป็นลิแกนด์ที่ดีกว่า สำหรับโนซิเซพทิน รีเซพเตอร์ orl-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |